Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00250770|
Recruitment Status : Recruiting
First Posted : November 8, 2005
Last Update Posted : May 12, 2016
The purposes of this study are the following:
- To further characterize and quantify both CSF-1 and colony-stimulating factor-1 receptor (CSF-1R) expression from additional tumor specimens, specifically, tumors of high grade and from metastatic sites.
- To assay using Enzyme-Linked ImmunoSorbent Assay (ELISA) sandwich monoclonal antibody methodology, CSF-1 expression in the peritoneal fluid and blood from patients with endometrial adenocarcinomas.
- Using immunohistochemistry, to evaluate the presence of staining for CSF-1 and CSF-1R from additional patients with endometrial adenocarcinomas, especially of high grades and from metastatic sites.
- To determine the extent of cytokine, specifically CSF-1, but also interleukin-1 (IL-1), IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF), production, in endometrial carcinoma cells in primary cell culture.
- To determine the responsiveness of epithelial cells on estrogen and antiestrogen binding, to determine if CSF-1 production is mediated, in these cells, by estrogen receptor binding, or alternative pathways of intracellular/cell-cell signal transduction.
- The ultimate objective of these experiments is to characterize CSF-1 expression from benign and tumor cells in order to identify steps in the CSF-1 activated signalling pathways that may represent potential targets for therapy.
|Condition or disease|
|Uterine Neoplasms Endometrial Neoplasms|
|Study Type :||Observational|
|Estimated Enrollment :||750 participants|
|Observational Model:||Case Control|
|Official Title:||CSF-1 and Other Cytokines in Human Endometrial Carcinogenesis|
|Study Start Date :||January 1998|
|Estimated Primary Completion Date :||January 2022|
|Estimated Study Completion Date :||January 2022|
Healthy postmenopausal and perimenopausal women with no history of endometrial carcinoma.
Women undergoing hysterectomy for benign conditions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00250770
|Contact: Suzanne Monroyemail@example.com|
|United States, New Mexico|
|University of New Mexico||Recruiting|
|Albuquerque, New Mexico, United States, 87131|
|Contact: Suzanne Monroy 505-272-6665 firstname.lastname@example.org|
|Principal Investigator:||Harriet Smith, MD||University of New Mexico|